Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Pfizer announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's ...

Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the ...